TOPIGEN Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, has announced the completion of patient enrollment in a Phase II safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8. The current clinical study builds on prior efficacy and safety data in a three-day study of TPI ASM8 in an allergen challenge model.
(more...)